Wet age-related macular degeneration (AMD) is receiving a lot of attention from industry, scientists and Wall Street these days, thanks to the enormous and rapid commercial success of new treatments for it.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.